In the News

The US Food and Drug Administration (FDA) approved burosumab-twza (Crysvita) injection to treat patients aged 2 years and older with tumour-induced osteomalacia (TIO). “Treatment for TIO focuses on identifying and removing the tumour that causes the disease; however, when that is not possible, [...
The US Food and Drug Administration (FDA) has approved canakinumab (Ilaris) injection for the treatment of active Still’s Disease, including adult-onset Still’s Disease (AOSD). “Prior to today’s approval, patients had no FDA-approved treatments for their disease, which can include symptoms such as...
The percentage of patients with hip osteoarthritis who had a hip replacement within 2 years of hip arthroscopy was unacceptably high at 68%, according to a study of more than 2,600 patients published in HIP International. Within 2 years of having had arthroscopy, about two-thirds of patients with...
Women with breast cancer treated with tamoxifen or aromatase inhibitors did not have an increased risk of rheumatoid arthritis (RA) compared with women with breast cancer who did not take either therapy, according to a study published in the Annals of the Rheumatic Diseases. Using nationwide...
The American College of Rheumatology (ACR) has published new guidelines for the management of gout. The updated guideline, published in Arthritis Care...

Conference Reports

By Eric Ramos

CHICAGO -- June 12, 2020 -- An intra-articular injection of JTA-004, a novel enhanced protein solution that is supplemented with hyaluronic acid and clonidine, improved pain in patients with knee osteoarthritis, according to a study presented at the 2020 Virtual Meeting of...

By Eric Ramos

CHICAGO -- June 11, 2020 -- A set of antibody biomarkers can help predict which patients with rheumatoid arthritis (RA) will respond to therapy, according to a study presented at the 2020 Virtual Meeting of the European League Against Rheumatism (EULAR).

“For...

By Eric Ramos

CHICAGO -- June 9, 2020 -- Long-term treatment with canakinumab was safe and effective for patients with colchicine-resistant familial Mediterranean fever, according to a study presented at the 2020 Virtual Meeting of the European League Against Rheumatism (EULAR).

“...

By Eric Ramos

CHICAGO -- June 9, 2020 -- Therapeutic drug monitoring in patients with rheumatic diseases who are starting treatment with infliximab does not appear to be superior to standard treatment in order to achieve remission, according to a study presented at the 2020 Virtual...

By Eric Ramos

CHICAGO -- June 8, 2020 -- Colchicine 1 mg/day for 12 weeks was not effective in improving pain, tender and swollen joint count, or grip strength in patients with symptomatic hand osteoarthritis, according to a study presented at the 2020 Virtual Meeting of the European...

Recently Published

Current Opinion in Rheumatology
James B Lilleker, Mark Roberts, Louise Diederichsen
Journal of Rheumatology
Atsuma Nishiwaki, Hitomi Kobayashi, Natsumi Ikumi, Yasuyuki Kobayashi, Isamu Yokoe, Kaita Sugiyama, Yoshihiro Matsukawa, Masami Takei, Noboru Kitamura
Journal of Rheumatology
Jyoti Panwar, Mirkamal Tolend, Lillian Lim, Shirley M Tse, Andrea S Doria, Ronald M Laxer, Jennifer Stimec
Journal of Rheumatology
Yudong Liu, Shulan Zhang, Changshe Xia, Jiali Chen, Chunhong Fan

Full-Text Articles

Journal of Rheumatology
John K Botson, John R P Tesser, Ralph Bennett, Howard M Kenney, Paul M Peloso, Katie Obermeyer, Brian LaMoreaux, Michael E Weinblatt, Jeff Peterson
Journal of Rheumatology
Linh Troung, Lila Pourzand, Elizabeth R Volkmann
Pediatric Rheumatology Online Journal
Achille Marino, Pamela F Weiss, Timothy G Brandon, Melissa A Lerman
Arthritis Research & Therapy
Mukundan Attur, Svetlana Krasnokutsky, Hua Zhou, Jonathan Samuels, Gregory Chang, Jenny Bencardino, Pamela Rosenthal, Leon Rybak, Janet L Huebner, Virginia B Kraus, Steven B Abramson
Arthritis Research & Therapy
Imke Redeker, Johanna Callhoff, Falk Hoffmann, Ursula Marschall, Hildrun Haibel, Joachim Sieper, Angela Zink, Denis Poddubnyy